Hermida Gerardo, Alvarez-Nuño Rodolfo, San Miguel-Izquierdo Jesús, González-Quijada Santiago, González-López Tomás José
Hematology Department, Hospital Universitario de Burgos, Burgos, Spain.
Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red Cáncer, Clínica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Oncol Ther. 2024 Mar;12(1):183-188. doi: 10.1007/s40487-024-00263-w. Epub 2024 Feb 2.
Clarkson's disease is a very rare entity characterised by acute episodes of systemic oedema and severe hypotension associated with paraproteinaemia. Its classical treatment relies on methylxanthine combined with terbutaline. Although this prophylactic therapy reduces the mortality rate, relapses are frequent. Eighty percent of patients with Clarkson's disease present with monoclonal gammopathy of unknown significance (MGUS). The risk of progression to multiple myeloma is 1% per year.
Here, we present a 49-year-old woman who suffered multiple such episodes requiring treatment in the intensive care unit. Treatment with terbutaline and theophylline was ineffective. She was diagnosed with multiple myeloma (MM) 8 years after the first of these acute episodes. Antimyeloma treatment with bortezomib and dexamethasone was started, followed by autologous haemopoietic transplantation, with no further acute episodes since then.
Our case is, to our knowledge, unique because eradication of MM was followed by complete disappearance of acute episodes of capillary leakage. Our case report is also the first to support the use of bortezomib and dexamethasone in this setting. Furthermore, autologous peripheral blood progenitor cell transplantation consolidated the MM stringent complete remission achieving a very long progression-free survival (> 11 years) of both MM and Clarkson's disease.
克拉克森病是一种非常罕见的疾病,其特征为伴有副蛋白血症的全身性水肿和严重低血压急性发作。其经典治疗方法是甲基黄嘌呤联合特布他林。尽管这种预防性治疗可降低死亡率,但复发很常见。80%的克拉克森病患者表现为意义未明的单克隆丙种球蛋白病(MGUS)。每年进展为多发性骨髓瘤的风险为1%。
在此,我们报告一名49岁女性,她经历了多次此类发作,需要在重症监护病房接受治疗。使用特布他林和茶碱治疗无效。在首次出现这些急性发作8年后,她被诊断为多发性骨髓瘤(MM)。开始使用硼替佐米和地塞米松进行抗骨髓瘤治疗,随后进行自体造血移植,此后未再出现急性发作。
据我们所知,我们的病例很独特,因为根除MM后毛细血管渗漏急性发作完全消失。我们的病例报告也是首个支持在此情况下使用硼替佐米和地塞米松的报告。此外,自体外周血祖细胞移植巩固了MM的严格完全缓解,实现了MM和克拉克森病非常长的无进展生存期(>11年)。